Teva Weighs Sale of $2 Billion Active Ingredients Unit
- Israeli group working with advisers to gauge interest in asset
- Health-care sector is defying broader dealmaking slump in 2023
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. is weighing options for its active ingredients business, including a possible sale, people with knowledge of the matter said, as takeovers of health-care assets continue to defy the global dealmaking slump.
The Israeli company is working with advisers as it seeks to gauge interest in the Teva API unit from potential buyers, according to the people. A deal could value the business at about $2 billion, they said.